Teva Pharmaceuticals USA is recalling 5,849 bottles of Matzim LA (diltiazem hydrochloride) Extended-Release Tablets, 240 mg. This recall was initiated because a specific lot of this prescription blood pressure and chest pain medication was distributed commercially when it was not intended for sale. Consumers should contact their healthcare provider or pharmacist if they have this medication, as it may not have met all commercial distribution standards.
The product was released into the supply chain due to a manufacturing process deviation where a lot not intended for commercial use was shipped. While the risk level is considered low, medications not intended for distribution may not meet all quality requirements, which could potentially impact the effectiveness or safety of the treatment.
Product return and pharmacist consultation.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.